Stocktoria

Novo Nordisk A/S NOVO-B.CO

DK · Nasdaq Copenhagen · XCSE · stock · Healthcare · website

Novo Nordisk A/S financials (annual)

Revenue
kr 176.95B kr 232.26B kr 290.40B kr 309.06B 2022202320242025
Net income
kr 55.52B kr 83.68B kr 100.99B kr 102.43B 2022202320242025
Free cash flow
kr 64.13B kr 70.01B kr 69.66B kr 28.99B 2022202320242025

Bars are annual figures from 2022 to 2025; red bars are negative (a loss or cash outflow).

MetricFY2025FY2024FY2023FY2022
Revenuekr 309.1Bkr 290.4Bkr 232.3Bkr 177.0B
Gross profitkr 250.3Bkr 245.9Bkr 196.5Bkr 148.5B
R&D expensekr 52.0Bkr 48.1Bkr 32.4Bkr 24.0B
SG&A expensekr 70.3Bkr 67.4Bkr 61.6Bkr 50.7B
Operating incomekr 127.7Bkr 128.3Bkr 102.6Bkr 74.8B
Interest expensekr 4.2Bkr 1.6Bkr 542.0Mkr 378.0M
Income taxkr 28.1Bkr 26.2Bkr 21.0Bkr 13.5B
Net incomekr 102.4Bkr 101.0Bkr 83.7Bkr 55.5B
EPS (diluted)kr 23.03kr 22.63kr 18.62kr 12.22
Operating cash flowkr 119.1Bkr 121.0Bkr 108.9Bkr 78.9B
Free cash flowkr 29.0Bkr 69.7Bkr 70.0Bkr 64.1B
Cash & equivalentskr 26.5Bkr 15.7Bkr 14.4Bkr 12.7B
Inventorykr 49.6Bkr 40.8Bkr 31.8Bkr 24.4B
Goodwillkr 19.8Bkr 20.0Bkr 4.5Bkr 4.6B
Total assetskr 542.9Bkr 465.6Bkr 314.5Bkr 241.3B
Total debtkr 131.0Bkr 102.8Bkr 27.0Bkr 25.8B
Total liabilitieskr 348.9Bkr 322.1Bkr 207.9Bkr 157.8B
Shareholders' equitykr 194.0Bkr 143.5Bkr 106.6Bkr 83.5B
Share buybackskr 1.4Bkr 20.2Bkr 29.9Bkr 24.1B

Growth · year-over-year · Revenue CAGR 20.4%

MetricFY2025FY2024FY2023FY2022
Revenue growth+6.4%+25.0%+31.3%—
Net income growth+1.4%+20.7%+50.7%—
EPS growth+1.8%+21.5%+52.4%—
Free cash flow growth-58.4%-0.5%+9.2%—

Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.

Computed from company filings · DK · as of 2025-12-31. Figures in DKK. Facts plus Stocktoria's own computed scores — not investment advice.